Drs. Maria Elena Bottazzi and Peter Hotez at the Center for Vaccine Development. Photo courtesy of Texas Children's Hospital

With the U.S. logging its highest single-day total of new COVID-19 cases (441,278 infections) and some 281, 808, 270 cases documented worldwide, new treatments worldwide are in major demand — especially in emerging nations.

To that end, Texas Children’s Hospital and Baylor College of Medicine announced a new COVID vaccine ready to deploy in India and soon, other underserved countries.

Corbevax, which is dubbed “The World’s COVID-19 Vaccine,” utilizes a traditional recombinant protein-based technology that will enable production at large scales, per a press release. That means the inoculation will be widely accessible to inoculate the global population.

This new vaccine was developed at Texas Children’s Hospital CVD and led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez — and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).

After completing two Phase III clinical trials involving more than 3000 subjects the vaccine was found to be safe, well tolerated, and immunogenic. Current research shows Corbevax notably effective against the Ancestral-Wuhan strain and the globally dominant Delta variant, press materials note.

Safe, streamlined, low-cost vaccines for middle- to low-income countries are central to the world’s fight against the COVID-19 pandemic, the two Houston organizations note. Indeed, without widespread vaccination of populations in the Global South, additional virus variants will arise, hindering the progress achieved by currently available vaccines in the United States and other Western countries, per research.

“This announcement is an important first step in vaccinating the world and halting the pandemic,” said Hotez in a statement. “Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant. Widespread and global vaccination with our Texas Children’s-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow.”

------

This article originally ran on CultureMap.

Texas Children's Hospital and Baylor College of Medicine are working on a new COVID-19 vaccine candidate. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston health care organizations team up for the 'people's vaccine'

COVID Collaboration

Two major health care institutions in Houston — Texas Children's Hospital and the Baylor College of Medicine — are a step closer to rolling out what they dub the "people's vaccine" for COVID-19.

The two institutions, along with India-based vaccine and pharmaceutical company Biological E Ltd., have gained approval to move ahead this month with Phase III clinicals trials in India of a COVID-19 vaccine candidate called Corbevax. The Texas Children's Hospital Center for Vaccine Development developed the vaccine's protein antigen, which was licensed from the Baylor College of Medicine's BCM Ventures commercialization arm.

Unlike COVID-19 vaccines in the U.S., Corbevax contains the so-called "spike protein" from the surface of the novel coronavirus. Once that protein is injected via a vaccine, the body is supposed to begin building immunity against the protein and thereby prevent serious illness.

Experts envision Corbevax being a readily available weapon in the global fight against the COVID-19 pandemic, thanks to the simple vaccine platform (like the one used to prevent Hepatitis B) and the ability to store the vaccine in normal refrigerated settings. The targets of this vaccine are children and mothers.

"In the midst of India's public health crisis, it is our hope that our Texas Children's and Baylor COVID-19 vaccine can be released for emergency authorization in India and in all countries in need of essential COVID-19 vaccinations," Dr. Peter Hotez, co-director of the Texas Children's Hospital Center for Vaccine Development, says in a June 9 news release.

India has reported more than 29 million cases of COVID-19, causing 354,000 deaths. The country's COVID-19 surge reached its peak in May.

"The vaccines currently available cannot be manufactured quick enough to meet supply shortages in low-income countries," Hotez says. "Our vaccine is truly 'the people's vaccine,' created to serve the most marginalized and underserved populations that are hardest hit by this pandemic. This is the vaccine that could be used to vaccinate the world."

In the Phase III trial, the two-dose Corbevax vaccine will be administered to about 1,200 people age 18 to 80 at 15 sites in India. A larger global study of Corbevax is in the works.

According to India.com, Corbevax could be the most affordable COVID-19 vaccine available in the nation of nearly 1.37 billion people, costing close to $7 for a two-dose regimen. The Indian government already has preordered 300 million doses of Corbevax, which has shown promise in Phase I and Phase II trials. The Phase II trial ended in April.

If the Phase III trial goes as planned, doses could be widely administered as soon as August. Biological E initially plans to produce 75 million to 80 million doses per month, according to media reports. The Indian company foresees manufacturing at least 1 billion doses by the end of 2022.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston wearable biosensing company closes $13M pre-IPO round

fresh funding

Wellysis, a Seoul, South Korea-headquartered wearable biosensing company with its U.S. subsidiary based in Houston, has closed a $13.5 million pre-IPO funding round and plans to expand its Texas operations.

The round was led by Korea Investment Partners, Kyobo Life Insurance, Kyobo Securities, Kolon Investment and a co-general partner fund backed by SBI Investment and Samsung Securities, according to a news release.

Wellysis reports that the latest round brings its total capital raised to about $30 million. The company is working toward a Korea Securities Dealers Automated Quotations listing in Q4 2026 or Q1 2027.

Wellysis is known for its continuous ECG/EKG monitor with AI reporting. Its lightweight and waterproof S-Patch cardiac monitor is designed for extended testing periods of up to 14 days on a single battery charge.

The company says that the funding will go toward commercializing the next generation of the S-Patch, known as the S-Patch MX, which will be able to capture more than 30 biometric signals, including ECG, temperature and body composition.

Wellysis also reports that it will use the funding to expand its Houston-based operations, specifically in its commercial, clinical and customer success teams.

Additionally, the company plans to accelerate the product development of two other biometric products:

  • CardioAI, an AI-powered diagnostic software platform designed to support clinical interpretation, workflow efficiency and scalable cardiac analysis
  • BioArmour, a non-medical biometric monitoring solution for the sports, public safety and defense sectors

“This pre-IPO round validates both our technology and our readiness to scale globally,” Young Juhn, CEO of Wellysis, said in the release. “With FDA-cleared solutions, expanding U.S. operations, and a strong AI roadmap, Wellysis is positioned to redefine how cardiac data is captured, interpreted, and acted upon across healthcare systems worldwide.”

Wellysis was founded in 2019 as a spinoff of Samsung. Its S-Patch runs off of a Samsung Smart Health Processor. The company's U.S. subsidiary, Wellysis USA Inc., was established in Houston in 2023 and was a resident of JLABS@TMC.

Elon Musk vows to launch solar-powered data centers in space

To Outer Space

Elon Musk vowed this week to upend another industry just as he did with cars and rockets — and once again he's taking on long odds.

The world's richest man said he wants to put as many as a million satellites into orbit to form vast, solar-powered data centers in space — a move to allow expanded use of artificial intelligence and chatbots without triggering blackouts and sending utility bills soaring.

To finance that effort, Musk combined SpaceX with his AI business on Monday, February 2, and plans a big initial public offering of the combined company.

“Space-based AI is obviously the only way to scale,” Musk wrote on SpaceX’s website, adding about his solar ambitions, “It’s always sunny in space!”

But scientists and industry experts say even Musk — who outsmarted Detroit to turn Tesla into the world’s most valuable automaker — faces formidable technical, financial and environmental obstacles.

Feeling the heat

Capturing the sun’s energy from space to run chatbots and other AI tools would ease pressure on power grids and cut demand for sprawling computing warehouses that are consuming farms and forests and vast amounts of water to cool.

But space presents its own set of problems.

Data centers generate enormous heat. Space seems to offer a solution because it is cold. But it is also a vacuum, trapping heat inside objects in the same way that a Thermos keeps coffee hot using double walls with no air between them.

“An uncooled computer chip in space would overheat and melt much faster than one on Earth,” said Josep Jornet, a computer and electrical engineering professor at Northeastern University.

One fix is to build giant radiator panels that glow in infrared light to push the heat “out into the dark void,” says Jornet, noting that the technology has worked on a small scale, including on the International Space Station. But for Musk's data centers, he says, it would require an array of “massive, fragile structures that have never been built before.”

Floating debris

Then there is space junk.

A single malfunctioning satellite breaking down or losing orbit could trigger a cascade of collisions, potentially disrupting emergency communications, weather forecasting and other services.

Musk noted in a recent regulatory filing that he has had only one “low-velocity debris generating event" in seven years running Starlink, his satellite communications network. Starlink has operated about 10,000 satellites — but that's a fraction of the million or so he now plans to put in space.

“We could reach a tipping point where the chance of collision is going to be too great," said University at Buffalo's John Crassidis, a former NASA engineer. “And these objects are going fast -- 17,500 miles per hour. There could be very violent collisions."

No repair crews

Even without collisions, satellites fail, chips degrade, parts break.

Special GPU graphics chips used by AI companies, for instance, can become damaged and need to be replaced.

“On Earth, what you would do is send someone down to the data center," said Baiju Bhatt, CEO of Aetherflux, a space-based solar energy company. "You replace the server, you replace the GPU, you’d do some surgery on that thing and you’d slide it back in.”

But no such repair crew exists in orbit, and those GPUs in space could get damaged due to their exposure to high-energy particles from the sun.

Bhatt says one workaround is to overprovision the satellite with extra chips to replace the ones that fail. But that’s an expensive proposition given they are likely to cost tens of thousands of dollars each, and current Starlink satellites only have a lifespan of about five years.

Competition — and leverage

Musk is not alone trying to solve these problems.

A company in Redmond, Washington, called Starcloud, launched a satellite in November carrying a single Nvidia-made AI computer chip to test out how it would fare in space. Google is exploring orbital data centers in a venture it calls Project Suncatcher. And Jeff Bezos’ Blue Origin announced plans in January for a constellation of more than 5,000 satellites to start launching late next year, though its focus has been more on communications than AI.

Still, Musk has an edge: He's got rockets.

Starcloud had to use one of his Falcon rockets to put its chip in space last year. Aetherflux plans to send a set of chips it calls a Galactic Brain to space on a SpaceX rocket later this year. And Google may also need to turn to Musk to get its first two planned prototype satellites off the ground by early next year.

Pierre Lionnet, a research director at the trade association Eurospace, says Musk routinely charges rivals far more than he charges himself —- as much as $20,000 per kilo of payload versus $2,000 internally.

He said Musk’s announcements this week signal that he plans to use that advantage to win this new space race.

“When he says we are going to put these data centers in space, it’s a way of telling the others we will keep these low launch costs for myself,” said Lionnet. “It’s a kind of powerplay.”

Johnson Space Center and UT partner to expand research, workforce development

onward and upward

NASA’s Johnson Space Center in Houston has forged a partnership with the University of Texas System to expand collaboration on research, workforce development and education that supports space exploration and national security.

“It’s an exciting time for the UT System and NASA to come together in new ways because Texas is at the epicenter of America’s space future. It’s an area where America is dominant, and we are committed as a university system to maintaining and growing that dominance,” Dr. John Zerwas, chancellor of the UT System, said in a news release.

Vanessa Wyche, director of Johnson Space Center, added that the partnership with the UT System “will enable us to meet our nation’s exploration goals and advance the future of space exploration.”

The news release noted that UT Health Houston and the UT Medical Branch in Galveston already collaborate with NASA. The UT Medical Branch’s aerospace medicine residency program and UT Health Houston’s space medicine program train NASA astronauts.

“We’re living through a unique moment where aerospace innovation, national security, economic transformation, and scientific discovery are converging like never before in Texas," Zerwas said. “UT institutions are uniquely positioned to partner with NASA in building a stronger and safer Texas.”

Zerwas became chancellor of the UT System in 2025. He joined the system in 2019 as executive vice chancellor for health affairs. Zerwas represented northwestern Ford Bend County in the Texas House from 2007 to 2019.

In 1996, he co-founded a Houston-area medical practice that became part of US Anesthesia Partners in 2012. He remained active in the practice until joining the UT System. Zerwas was chief medical officer of the Memorial Hermann Hospital System from 2003 to 2008 and was its chief physician integration officer until 2009.

Zerwas, a 1973 graduate of the Houston area’s Bellaire High School, is an alumnus of the University of Houston and Baylor College of Medicine.